
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd is experiencing a notable increase in its equipment utilization rate, which has risen by over 50% since the establishment of its investment arrangement, signaling growing demand for its proprietary Deep TMS technology. Additionally, the company is navigating towards accelerated revenue growth through strategic investments and gaining traction in both pay-per-use models and the neurologist specialist prescriber segment, enhancing its market positioning. The ongoing clinical trials for various psychiatric, neurological, and addiction disorders further underline BrainsWay's commitment to expanding its treatment offerings, contributing to a fundamentally positive outlook on its financial trajectory.
Bears say
BrainsWay Ltd faces significant risks that contribute to a negative outlook on its stock, including a slower-than-expected adoption of its Deep TMS systems, which could hinder revenue generation. Furthermore, the company's failure to expand reimbursement options and market access presents an ongoing challenge that may restrict growth potential. Lastly, the inability to progress in developing Deep TMS for additional indications, coupled with the potential for long-term dilution, adds further uncertainty to its financial stability and future expansion prospects.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares